Detailed data about EDSS step changes in each patient/group and the activity status (relapse or MRI activity) in each patient
| . | Pre-study year + run in period . | First cycle of treatment . | Second cycle of treatment . |
|---|---|---|---|
| Patients with activitya | |||
| Placebo (n = 16) | 9 | 8 | 12 |
| MSC-IV (n = 16) | 10 | 6 | 9 |
| MSC-IT (n = 16) | 9 | 5 | 1 |
| Patients with worsening | |||
| Placebo (n = 16) | 14 | 7 (5 who were active before the start of treatment and 2 who were non-active) | 8 (6 who were active before the start of treatment and 2 who were non-active) |
| ΔEDSS | +0.5; +0.5; +0.5; +0.5; +0.5; +0.5; +1.0; +1.0; +1.0; +1.0; +1.5; +1.5; +1.5; +2.0 | +0.5; +0.5; +0.5; +0.5; +0.5; +1.0; +1.5 | +0.5; +0.5; +0.5; +0.5; +0.5; +0.5; +1.0; +1.0 |
| MSC-IV (n = 16) | 15 | 1 | 3 |
| ΔEDSS | +0.5; +0.5; +0.5; +0.5; +1.0; +1.0; +1.0; +1.0; +1.0; +1.0; +1.0; +1.5; +1.5; +1.5; +2.5 | +0.5 | +0.5; +0.5; +0.5 |
| MSC-IT (n = 16) | 15 | 2 | 0 |
| ΔEDSS | +0.5; +0.5; +0.5; +0.5; +1.0; +1.0; +1.0; +1.0; +1.5; +1.5; +1.5; +1.5; +2.0; +2.0; +2.0 | +0.5; +0.5 | − |
| Patients with improvement | |||
| Placebo (n = 16) | 0 | 0 | 1 −0.5 |
| MSC-IV (n = 16) | 0 | 3 | 6 (4 who were active before the start of treatment and 2 who were non-active) |
| ΔEDSS | − | −0.5; −0.5; −0.5 | −0.5; −0.5; −0.5; −1.0; −1.0 |
| MSC-IT (n = 16) | 0 | 2 | 11 (6 who were active before the start of treatment and 5 who were non-active) |
| ΔEDSS | − | −0.5; −0.5 | −0.5; −0.5; −0.5; −0.5; −0.5; −0.5; −0.5 − 0.5; −0.5; −0.5; −1.0 |
| . | Pre-study year + run in period . | First cycle of treatment . | Second cycle of treatment . |
|---|---|---|---|
| Patients with activitya | |||
| Placebo (n = 16) | 9 | 8 | 12 |
| MSC-IV (n = 16) | 10 | 6 | 9 |
| MSC-IT (n = 16) | 9 | 5 | 1 |
| Patients with worsening | |||
| Placebo (n = 16) | 14 | 7 (5 who were active before the start of treatment and 2 who were non-active) | 8 (6 who were active before the start of treatment and 2 who were non-active) |
| ΔEDSS | +0.5; +0.5; +0.5; +0.5; +0.5; +0.5; +1.0; +1.0; +1.0; +1.0; +1.5; +1.5; +1.5; +2.0 | +0.5; +0.5; +0.5; +0.5; +0.5; +1.0; +1.5 | +0.5; +0.5; +0.5; +0.5; +0.5; +0.5; +1.0; +1.0 |
| MSC-IV (n = 16) | 15 | 1 | 3 |
| ΔEDSS | +0.5; +0.5; +0.5; +0.5; +1.0; +1.0; +1.0; +1.0; +1.0; +1.0; +1.0; +1.5; +1.5; +1.5; +2.5 | +0.5 | +0.5; +0.5; +0.5 |
| MSC-IT (n = 16) | 15 | 2 | 0 |
| ΔEDSS | +0.5; +0.5; +0.5; +0.5; +1.0; +1.0; +1.0; +1.0; +1.5; +1.5; +1.5; +1.5; +2.0; +2.0; +2.0 | +0.5; +0.5 | − |
| Patients with improvement | |||
| Placebo (n = 16) | 0 | 0 | 1 −0.5 |
| MSC-IV (n = 16) | 0 | 3 | 6 (4 who were active before the start of treatment and 2 who were non-active) |
| ΔEDSS | − | −0.5; −0.5; −0.5 | −0.5; −0.5; −0.5; −1.0; −1.0 |
| MSC-IT (n = 16) | 0 | 2 | 11 (6 who were active before the start of treatment and 5 who were non-active) |
| ΔEDSS | − | −0.5; −0.5 | −0.5; −0.5; −0.5; −0.5; −0.5; −0.5; −0.5 − 0.5; −0.5; −0.5; −1.0 |
aActive patients: those with relapse or MRI activity during the year prior to inclusion.
Detailed data about EDSS step changes in each patient/group and the activity status (relapse or MRI activity) in each patient
| . | Pre-study year + run in period . | First cycle of treatment . | Second cycle of treatment . |
|---|---|---|---|
| Patients with activitya | |||
| Placebo (n = 16) | 9 | 8 | 12 |
| MSC-IV (n = 16) | 10 | 6 | 9 |
| MSC-IT (n = 16) | 9 | 5 | 1 |
| Patients with worsening | |||
| Placebo (n = 16) | 14 | 7 (5 who were active before the start of treatment and 2 who were non-active) | 8 (6 who were active before the start of treatment and 2 who were non-active) |
| ΔEDSS | +0.5; +0.5; +0.5; +0.5; +0.5; +0.5; +1.0; +1.0; +1.0; +1.0; +1.5; +1.5; +1.5; +2.0 | +0.5; +0.5; +0.5; +0.5; +0.5; +1.0; +1.5 | +0.5; +0.5; +0.5; +0.5; +0.5; +0.5; +1.0; +1.0 |
| MSC-IV (n = 16) | 15 | 1 | 3 |
| ΔEDSS | +0.5; +0.5; +0.5; +0.5; +1.0; +1.0; +1.0; +1.0; +1.0; +1.0; +1.0; +1.5; +1.5; +1.5; +2.5 | +0.5 | +0.5; +0.5; +0.5 |
| MSC-IT (n = 16) | 15 | 2 | 0 |
| ΔEDSS | +0.5; +0.5; +0.5; +0.5; +1.0; +1.0; +1.0; +1.0; +1.5; +1.5; +1.5; +1.5; +2.0; +2.0; +2.0 | +0.5; +0.5 | − |
| Patients with improvement | |||
| Placebo (n = 16) | 0 | 0 | 1 −0.5 |
| MSC-IV (n = 16) | 0 | 3 | 6 (4 who were active before the start of treatment and 2 who were non-active) |
| ΔEDSS | − | −0.5; −0.5; −0.5 | −0.5; −0.5; −0.5; −1.0; −1.0 |
| MSC-IT (n = 16) | 0 | 2 | 11 (6 who were active before the start of treatment and 5 who were non-active) |
| ΔEDSS | − | −0.5; −0.5 | −0.5; −0.5; −0.5; −0.5; −0.5; −0.5; −0.5 − 0.5; −0.5; −0.5; −1.0 |
| . | Pre-study year + run in period . | First cycle of treatment . | Second cycle of treatment . |
|---|---|---|---|
| Patients with activitya | |||
| Placebo (n = 16) | 9 | 8 | 12 |
| MSC-IV (n = 16) | 10 | 6 | 9 |
| MSC-IT (n = 16) | 9 | 5 | 1 |
| Patients with worsening | |||
| Placebo (n = 16) | 14 | 7 (5 who were active before the start of treatment and 2 who were non-active) | 8 (6 who were active before the start of treatment and 2 who were non-active) |
| ΔEDSS | +0.5; +0.5; +0.5; +0.5; +0.5; +0.5; +1.0; +1.0; +1.0; +1.0; +1.5; +1.5; +1.5; +2.0 | +0.5; +0.5; +0.5; +0.5; +0.5; +1.0; +1.5 | +0.5; +0.5; +0.5; +0.5; +0.5; +0.5; +1.0; +1.0 |
| MSC-IV (n = 16) | 15 | 1 | 3 |
| ΔEDSS | +0.5; +0.5; +0.5; +0.5; +1.0; +1.0; +1.0; +1.0; +1.0; +1.0; +1.0; +1.5; +1.5; +1.5; +2.5 | +0.5 | +0.5; +0.5; +0.5 |
| MSC-IT (n = 16) | 15 | 2 | 0 |
| ΔEDSS | +0.5; +0.5; +0.5; +0.5; +1.0; +1.0; +1.0; +1.0; +1.5; +1.5; +1.5; +1.5; +2.0; +2.0; +2.0 | +0.5; +0.5 | − |
| Patients with improvement | |||
| Placebo (n = 16) | 0 | 0 | 1 −0.5 |
| MSC-IV (n = 16) | 0 | 3 | 6 (4 who were active before the start of treatment and 2 who were non-active) |
| ΔEDSS | − | −0.5; −0.5; −0.5 | −0.5; −0.5; −0.5; −1.0; −1.0 |
| MSC-IT (n = 16) | 0 | 2 | 11 (6 who were active before the start of treatment and 5 who were non-active) |
| ΔEDSS | − | −0.5; −0.5 | −0.5; −0.5; −0.5; −0.5; −0.5; −0.5; −0.5 − 0.5; −0.5; −0.5; −1.0 |
aActive patients: those with relapse or MRI activity during the year prior to inclusion.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
